Schonfeld Strategic Advisors LLC decreased its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 90.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,500 shares of the company's stock after selling 380,500 shares during the quarter. Schonfeld Strategic Advisors LLC owned about 0.06% of Bicycle Therapeutics worth $595,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in Bicycle Therapeutics by 79.3% in the third quarter. Geode Capital Management LLC now owns 38,335 shares of the company's stock worth $868,000 after acquiring an additional 16,958 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Bicycle Therapeutics in the 3rd quarter valued at $10,028,000. JPMorgan Chase & Co. boosted its holdings in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after purchasing an additional 1,782 shares in the last quarter. Avior Wealth Management LLC acquired a new position in Bicycle Therapeutics during the fourth quarter worth $57,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after buying an additional 2,191 shares during the last quarter. Institutional investors and hedge funds own 86.15% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on BCYC shares. B. Riley lowered their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Morgan Stanley set a $17.00 price objective on shares of Bicycle Therapeutics and gave the stock an "equal weight" rating in a research note on Monday. HC Wainwright reiterated a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. JMP Securities cut their target price on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a research report on Friday, May 2nd. Finally, Stephens reiterated an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.00.
Read Our Latest Stock Analysis on BCYC
Bicycle Therapeutics Trading Up 2.0 %
Shares of BCYC stock opened at $8.34 on Friday. Bicycle Therapeutics plc has a 12 month low of $6.10 and a 12 month high of $28.67. The company has a market capitalization of $577.14 million, a P/E ratio of -2.53 and a beta of 1.60. The stock has a 50 day moving average of $8.44 and a two-hundred day moving average of $13.84.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $9.98 million during the quarter, compared to the consensus estimate of $8.67 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Sell-side analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.
About Bicycle Therapeutics
(
Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Featured Articles
Want to see what other hedge funds are holding BCYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
